Bioshares Etf Profile

BBC -  USA Etf  

USD 47.60  0.19  0.40%

Bioshares Biotech is trading at 47.60 as of the 16th of September 2021, a -0.4 percent down since the beginning of the trading day. The etf's open price was 47.79. Bioshares Biotech has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Bioshares Biotech Clinical are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 19th of January 2021 and ending today, the 16th of September 2021. Click here to learn more.
 Market Performance
0 of 100
  Odds Of Distress
Less than 1

Bioshares Biotech Etf Profile

The investment seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Clinical Trials Index. Bioshares Biotech is traded on NYSEArca Exchange in the United States. more on Bioshares Biotech
Bioshares Biotech is unlikely to experience financial distress in the next 2 years
The fund holds 98.68% of its assets under management (AUM) in equities
Legal NameBioshares Biotech Clinical
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Bioshares Biotech's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
IssuerVirtus
DescriptionVirtus LifeSci Biotech Clinical Trials ETF
Inception Date2014-12-16
BenchmarkLifeSci Biotechnology Clinical Trials Index
Entity TypeRegulated Investment Company
Asset Under Management38.26 Million
Average Trading Valume3,115.8
Asset TypeEquity
CategorySector
FocusHealth Care
Market ConcentrationDeveloped Markets
RegionNorth America
AdministratorVirtus ETF Solutions, LLC
AdvisorVirtus ETF Advisers LLC
CustodianThe Bank of New York Mellon Corporation
DistributorETF Distributors LLC
Portfolio ManagerMatthew B. Brown, Seth Kadushin
Transfer AgentThe Bank of New York Mellon Corporation
Fiscal Year End31-Oct
ExchangeNYSE Arca, Inc.
Number of Constituents198
Market MakerVirtu Financial
Total Expense0.79
Management Fee0.79
Nav Price44.24
Two Hundred Day Average49.01
Ytd0.71%
Average Daily Volume In Three Month3.46k
Fifty Two Week Low37.18
As Of Date30th of June 2021
Average Daily Volume Last 10 Day3.57k
Fifty Two Week High62.6
One Month4.00%
Fifty Day Average45.96
Three Month-2.79%
Bioshares Biotech Clinical [BBC] is traded in USA and was established 2014-12-16. The fund is classified under Health category within Virtus family. Bioshares Biotech currently have 42.53 M in assets under management (AUM). , while the total return for the last 3 years was 15.17%.
Check Bioshares Biotech Probability Of Bankruptcy

Geographic Allocation (%)

Sector Allocation (%)

Investors will always prefer to have their portfolios divercified against different sectors. The broad sector allocation increases the possibility of making a profit or at least avoiding a loss. However, this may also reduce the expected return on Bioshares Etf. Generally, it depends on diversification level and type but usually, the broader the sector allocation, the less risk can be expected from holding Bioshares Biotech , and the less return is expected.

Top Bioshares Biotech Clinical Constituents

Bioshares Biotech Target Price Odds Analysis

What are Bioshares Biotech's target price odds to finish over the current price? Depending on a normal probability distribution, the odds of Bioshares Biotech jumping above the current price in 90 days from now is about 29.24%. The Bioshares Biotech Clinical probability density function shows the probability of Bioshares Biotech etf to fall within a particular range of prices over 90 days. Considering the 90-day investment horizon Bioshares Biotech has a beta of 0.3538 suggesting as returns on the market go up, Bioshares Biotech average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Bioshares Biotech Clinical will be expected to be much smaller as well. Additionally, the company has an alpha of 0.2775, implying that it can generate a 0.28 percent excess return over DOW after adjusting for the inherited market risk (beta).
 Odds Down 47.6HorizonTargetOdds Up 47.6 
70.51%90 days
 47.60 
29.24%
Based on a normal probability distribution, the odds of Bioshares Biotech to move above the current price in 90 days from now is about 29.24 (This Bioshares Biotech Clinical probability density function shows the probability of Bioshares Etf to fall within a particular range of prices over 90 days) .

Bioshares Biotech Major Institutional Holders

Institutional Holdings refers to the ownership stake in Bioshares Biotech that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Bioshares Biotech's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Bioshares Biotech's value.
InstituionSecurity TypeTotal SharesValue
Royal Bank Of CanadaFund Units105 K5.2 M
View Bioshares Biotech Diagnostics

Bioshares Biotech Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Bioshares Biotech market risk premium is the additional return an investor will receive from holding Bioshares Biotech long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Bioshares Biotech. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Bioshares Biotech's alpha and beta are two of the key measurements used to evaluate Bioshares Biotech's performance over the market, the standard measures of volatility play an important role as well.

Bioshares Biotech Technical Analysis

Transformation
The output start index for this execution was zero with a total number of output elements of seventeen. Bioshares Biotech Square Root Of Price Series is a mathematical transformation function. View also all equity analysis or get more info about square root of price series math transform indicator.

Bioshares Biotech Against Markets

Picking the right benchmark for Bioshares Biotech etf is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Bioshares Biotech etf price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Bioshares Biotech is critical whether you are bullish or bearish towards Bioshares Biotech Clinical at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Bioshares Biotech without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio File Import Now

   

Portfolio File Import

Quickly import all of your third-party portfolios from your local drive in csv format
All  Next Launch Module
Continue to Trending Equities. Note that the Bioshares Biotech information on this page should be used as a complementary analysis to other Bioshares Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Complementary Tools for Bioshares Etf analysis

When running Bioshares Biotech price analysis, check to measure Bioshares Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bioshares Biotech is operating at the current time. Most of Bioshares Biotech's value examination focuses on studying past and present price action to predict the probability of Bioshares Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Bioshares Biotech's price. Additionally, you may evaluate how the addition of Bioshares Biotech to your portfolios can decrease your overall portfolio volatility.
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
The market value of Bioshares Biotech is measured differently than its book value, which is the value of Bioshares that is recorded on the company's balance sheet. Investors also form their own opinion of Bioshares Biotech's value that differs from its market value or its book value, called intrinsic value, which is Bioshares Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bioshares Biotech's market value can be influenced by many factors that don't directly affect Bioshares Biotech underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bioshares Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Bioshares Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bioshares Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.